Knight Therapeutics Inc. Q2 2025 Earnings Recap

GUD.TO Q2 2025 August 8, 2025

Get alerts when GUD.TO reports next quarter

Knight Therapeutics reported strong second-quarter results, achieving record adjusted revenues of CAD 108.5 million, a 15% year-over-year increase, alongside significant strategic business development activities.

Earnings Per Share Miss

$-0.13 vs $0.03 est.

-522.3% surprise

Revenue Beat

107358000 vs 106641500 est.

+0.7% surprise

Market Reaction

1-Day -1.57%

5-Day +0.94%

30-Day -0.16%

See GUD.TO alongside your other holdings

Add to your portfolio — free

Key Takeaways

Adjusted EBITDA for Q2 2025 reached CAD 15.5 million, translating to CAD 0.16 per share, indicating strong operational performance.
The oncology and infectious disease portfolios saw robust growth, with revenue increases of 20% and 26% respectively, driven by new product launches and strategic transactions.
The company expanded its product offerings significantly, adding over 50 products through recent acquisitions, enhancing future growth potential.
Gross margin slightly declined to 46% due to product mix changes and severance costs from operational restructuring.
A new $50 million revolving credit facility has been secured, with plans to increase it to support ongoing acquisitions and growth initiatives in Canada and Latin America.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit GUD.TO on AllInvestView.

Next Q3 2025